Author's Reply.

Nguyen, Joehl T; Cole, Ashley L; Leech, Ashley A; Wood, William A; Dusetzina, Stacie B

Author's Reply.

Nguyen, Joehl T; Cole, Ashley L; Leech, Ashley A; Wood, William A; Dusetzina, Stacie B.

Afiliación

Nguyen JT; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cole AL; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC, USA.
Leech AA; Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA.
Wood WA; Division of Hematology and Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Dusetzina SB; Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Electronic address: s.dusetzina@vanderbilt.edu.

Value Health ; 24(7): 1086-1087, 2021 07.

Article en En | MEDLINE | ID: mdl-34243833

Asunto(s)

Análisis Costo-Beneficio; Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/economía; Inhibidores de Proteínas Quinasas/uso terapéutico; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Análisis Costo-Beneficio / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google